Nutriband Advances Abuse-Deterrent Transdermal Drug Technology with Strategic Partnerships
TL;DR
Nutriband's AVERSA technology enhances drug safety, offering a competitive advantage in the transdermal pharmaceutical market.
AVERSA technology integrates aversive agents into transdermal patches to prevent drug abuse and misuse, safeguarding patient access.
Nutriband's AVERSA technology promotes safe drug usage, improving patient care and reducing the risk of substance abuse.
Nutriband secures patents globally for AVERSA technology, partnering with Kindeva Drug Delivery to advance abuse-deterrent fentanyl patches.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc., a pharmaceutical development company, is making significant strides in drug safety technology with its AVERSA platform, which aims to reduce the potential for drug abuse in transdermal patches. The company has secured key strategic developments to advance its abuse-deterrent technology for transdermal medications.
The AVERSA technology can be integrated into any transdermal patch, with a particular focus on high-risk medications like fentanyl. By incorporating aversive agents, the technology seeks to prevent drug misuse, diversion, and accidental exposure while ensuring patients retain access to necessary medications.
The company has built a robust intellectual property portfolio, with patents granted across multiple countries including the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China. This global patent protection underscores the potential significance of the AVERSA technology in addressing pharmaceutical safety challenges.
In April 2024, Nutriband closed an $8.4 million financing round specifically to support the commercial development of AVERSA Fentanyl. Furthermore, the company formalized a long-term exclusive partnership with Kindeva Drug Delivery in February 2025, which will help facilitate the pathway to market for its innovative transdermal patch technology.
The development of abuse-deterrent drug delivery systems represents a critical advancement in pharmaceutical safety, potentially reducing the risks associated with opioid medications while maintaining therapeutic effectiveness. Nutriband's approach could significantly impact healthcare by providing a mechanism to mitigate drug abuse risks without compromising patient treatment options.
Curated from InvestorBrandNetwork (IBN)
